The latest international news, analysis and features on the HIV epidemic from AVERT. Share your views and expertise with your peers in the comments box below the articles.
Adherence challenges with pre-exposure prophylaxis (PrEP) could be overcome if experimental long-acting HIV drug is found to be effective and acceptable.
Near-universal uptake of HIV testing among men who were given self-tests by their partners in Kenya shows its feasibility as an intervention to reach hard-to-reach groups.
Injecting drug use accounted for 9% of all new HIV infections in the USA in 2014 – but new demographic trends among people who inject drugs present new challenges for the HIV response.
The world’s second largest antiretroviral treatment programme is now reaching just under half of all those living with HIV in India, but challenges remain to achieve UNAIDS’ 90-90-90 Fast-Track targets.
Treatment access gains are to be applauded – but we will get nowhere if we don’t prevent more new infections and reach out to key affected populations.
Drug policy based on prohibition hasn't worked. It's time to build on the success of partial-decriminalisation models with an emphasis on health and human rights, says new report.
New HIV infections among adolescent girls and young women fell by only 6% between 2010 and 2015. This puts the HIV response severely off-track to reach the UNAIDS 2020 Fast-Track Targets.
People who inject drugs are increasingly left behind in the HIV response, with limited access to harm reduction services that secure their rights and their health.
Concerns have been raised about the shortage of antiretroviral drugs available for people living with HIV in Venezuela, which is in the midst of a mounting health crisis.
Key affected populations in middle-income countries are hardest hit by global funding cuts, but Ukraine has made a bold move to fund its own response for people who inject drugs.